Abivax says no rush for a deal, confident June trial data will help

Abivax’s leadership signaled that the company is not rushing into a sale and expects key Phase 3 maintenance data due in June to materially improve its leverage in any partnership or acquisition talks.

The situation intensified after French press reports suggested Abivax had given AstraZeneca an exclusive access period; Abivax dismissed those reports as unfounded. Earlier reports had also linked the group to interest from other large pharma names, but company executives have repeatedly characterized such speculation as market noise. The company’s obefazimod (ABX464) maintenance readout is widely viewed as the pivotal near-term milestone.

Markets have reacted sharply to data and deal rumours in the past: positive Phase 3 announcements previously drove strong share gains, and surveys of investors and analysts have identified Abivax as a top takeover candidate in the current M&A environment. That backdrop keeps acquisition chatter alive while investors await concrete regulatory and clinical milestones that would de‑risk the asset for potential buyers.

The broader context is Abivax’s clinical program: the company reported encouraging results in its 8‑week induction trials and continues to advance the 44‑week maintenance study that will inform long‑term efficacy and safety. Company statements and industry coverage stress that a positive maintenance readout would accelerate regulatory filings and substantially change valuation dynamics for any strategic discussions.

Analysts caution that while takeover speculation may continue, the timing and terms will hinge on the June data and subsequent regulatory dialogue. Management’s public stance—favoring clinical substantiation over hasty dealmaking—suggests Abivax aims to capture maximum value from its pipeline rather than accept early offers, a position that could lead to higher premiums if the readout confirms durable benefit. Investors will watch the data release and any formal approaches closely.